Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals shares soared over 40 percent on nearly 12-times the average daily volume Tuesday. The company has reported that Zerenex, its treatment for kidney failure, met primary and all key secondary endpoints in a recent Phase 3 study.
Going forward ... (see research report)
Subscribe to News Feeds